Friday, November 19, 2021, 08.25 a.m.
Thai research team launches SARS-CoV-2 operation Press the dangerous covid virus ‘weak’
19 November 2021 Dr. Anan Chongkaewwatana, virologist Director of Animal Health and Management Innovation Research Group National Center for Genetic Engineering and Biotechnology (Biotech), National Science and Technology Development Agency (NSTDA) posted a message via Facebook. It has the following content…
The virology research team of Biotech, NSTDA, in addition to developing a vaccine for COVID-19, another task that we have been assigned through a 64-year loan budget (through the National Vaccine Institute) is to develop a method to create the SARS virus. -CoV-2 up in the lab
By means of genetic engineering to deliver genetic material like that of a natural virus into cells. This allows the cells to produce viral particles on their own without the need for viruses isolated from infected patients and cultured in normal cells as usual.
Called Reverse Genetics, this technique is the signature technique of Biotech’s viral team. Because it has been successful with many viruses in the past, such as the influenza virus. Swine Corona Virus, PRRS Virus in Swine, Newcastle Disease Virus in Chicken and many more.
This technology can help us control the creation of viruses (in other words, playing the cards above viruses) because we have the virus’ genetic code in hand. together with the body of knowledge that we know more about the coviral virus We can change the COVID-19 virus. that is dangerous to become a weak virus only by adjusting the key position of the virus
Become a model vaccine that many people want. There is no need to wait for the virus to change naturally that can take years. Or it might not happen at all. Or we can create a virus with a thorn protein of a strain of concern to prepare for vaccine development. before the actual outbreak in Thailand
Or we can modify the virus to express the desired protein, such as a fluorescent protein. And the virus can be tested for the properties of drugs, herbs or antiviral chemicals. In the future, if a new coronavirus emerges This technology will be able to continue to use.
With a biosafety level 3 (BSL-3) structure that works efficiently. As a result, the research team now has the same system for generating the SARS-CoV-2 virus in many countries before.
This image is a cell that has been created by a virus that can infect and multiply. In addition, the research team was able to carry a red fluorescent gene with a delta virus. To take advantage of dyeing or traditional methods that take a long time
It is another work that the Biotech virus research team NSTDA is proud of. Thanks to research grants supporting the creation of the BSL-3 chamber and research grants supporting making this technology possible. able to compete with other research teams abroad
-005
.
